THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
As of January 15, 2025, third line (3L) data showed median overall survival (OS) of 16.9 months for the 22 NSCLC patients who received at least one dose of THIO (the intent-to-treat population ...
MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...
The trial evaluates THIO, a telomere-targeting agent, in combination with Regeneron (NASDAQ:REGN)'s cemiplimab, an immune checkpoint inhibitor, in patients who have not responded to at least two ...
GlobalData on MSN7d
MAIA’s lung cancer therapy 99% more likely to improve OS over chemo aloneA treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...
MAIA Biotechnology, Inc. (NYSEAMERICAN: MAIA) disclosed information relating to its Phase 2 THIO-101 trial in advanced non-small cell lung cancer through a press release on February 4, 2025. According ...
The National Anti-Violence and Sexual Harassment Helpline received about 11,600 calls in 2023, up from 10,800 in 2022. Read ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
A semi-detached house on Coldstream Avenue, located in the prestigious Frankel Estate in the East, has been listed for $12.3 ...
The setting up of Lionheart Advocates aligns with recent efforts by the government to curb the abuse of court processes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback